FDA Grants Priority Review to Frontline Nivolumab-Ipilimumab Combo for NSCLC
January 16th 2020The FDA accepted and granted priority review to the supplemental biologics license application for nivolumab in combination with ipilimumab for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer.
Endocrine Toxicities May Be a Unique AE Associated with Immunotherapy
August 23rd 2019Like most other adverse events (AEs), nurses play a vital role in monitoring for and managing endocrine toxicities associated with immunotherapy treatment; however, these may be more unique than others, according to Marianne Davies, DNP, RN, CNS, ACNP-BC, AOCNP.
Patient Navigation Project Builds Foundation to Improve Breast Cancer Outcomes
June 27th 2019With a goal of championing the value of patient navigators, Susan G. Komen Greater New York City and NYU Langone have teamed up to provide patients with improved care in Brooklyn through a new patient navigation project.
Ongoing TRANSCEND Trial May Offer Hope to MCL Subset
June 12th 2019The treatment landscape for mantle cell lymphoma (MCL) is rapidly evolving, though patients with relapsed/refractory disease tend to still have poorer outcomes than others; however, hope may be on the horizon, according to Luhua (Michael) Wang, MD.
PARP Inhibitor Improves PFS in Pancreatic Cancer Subset
June 3rd 2019Maintenance therapy with olaparib (Lynparza) significantly improved progression-free survival (PFS) compared with placebo among patients with germline BRCA-mutated metastatic pancreatic cancer, according to results from the phase III POLO trial presented at the 2019 ASCO Annual Meeting.
FDA Grants Priority Review to Combination Regimen to Treat Multiple Myeloma
May 31st 2019The FDA granted a priority review to daratumumab (Darzalex) in combination with bortezomib (Velcade), thalidomide and dexamethasone (Vtd) for the front-line treatment of newly diagnosed patients with multiple myeloma who are candidates for autologous stem cell transplant.
Researchers Address Unmet Need in Bladder Cancer Detection
May 17th 2019Two new urine tests currently being investigated for bladder cancer detection and monitoring have demonstrated more than 90% sensitivity and specificity – highlighting the potential for addressing an unmet need among this patient population.
Lenalidomide Offers Patients With Smoldering Myeloma Option to Prevent Progression
May 16th 2019Lenalidomide (Revlimid) significantly reduced the risk for smoldering multiple myeloma to progress to cancer among patients with moderate to high risk, according to findings from the phase II/III E3A06 trial to be presented at the 2019 ASCO Annual Meeting.